Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.

Pharmaceutical Technology
Volume 35, Issue 6, pp. 50-54


This study focused on identifying a precipitation inhibitor that could inhibit or reduce drug precipitation from Labrasol formulations. Pluronic F127 was a potent agent for inhibiting precipitation of the tested compounds out of Labrasol formulations. Combinations of Pluronic F127 with Labrasol inhibited drug precipitation to a greater extent than Pluronic F127 did alone. This synergistic inhibitory effect was demonstrated with two poorly water-soluble compounds. In place of the complicated, multiple-component emulsion systems reported in the literature, Pluronic F127 can be added as the precipitation inhibitor and mixed with Labrasol. The Pluronic F127–Labrasol formulation is simple, easy to process and manufacture, and has advantages for scale-up and cost because it uses existing formulation processes and commercially available facilities. Adding Pluronic F127 into Labrasol formulations can improve them by inhibiting drug precipitation upon dilution.

Table II: I333/I338 value of the vibrational-emission spectrum of pyrene.
Pyrene was used to explore the underlying mechanism for inhibiting drug precipitation by Pluronic F127 in Labrasol formulations in this study. Pyrene has been widely used to probe the microenvironment of particles, such as micelles, microparticles, nanoparticles, and proteins. The I333/I338 ratio in the vibrational emission spectrum of pyrene indicated the particles' micropolarity. Low I333/I338 values represent more hydrophobic microenvironments than higher values do (18–20). The pyrene study results suggested that adding Pluronic F127 into Labrasol reduced the I1/I3 value significantly (see Table II), thus indicating the formation of an increasingly hydrophobic microenvironment. The increasingly hydrophobic microenvironment could be attributed to hydrophobic interaction between surfactants or to the hydrogen binding observed in other mixed micelles (18, 21, 22). This increasingly hydrophobic microenvironment enhances the hydrophobic interaction of drugs with hydrophobic cores of mixed surfactants, as reported previously (23, 24). The microenvironment therefore holds the drug more tightly and inhibits drug precipitation upon dilution. In contrast, when Pluronic F127 was added into PEG 400 or NMP, the I333/I338 value of these mixtures did not decrease (see Table 2). No hydrophobic microenvironment was formed because PEG 400 and NMP are highly hydrophilic solvents.

The results agreed with previous findings that the selected surfactant mixtures can result in more hydrophobic cores than individual mixtures (18, 20, 22, 25, 26). The synergistic results of Pluronic F127 with Labrasol in this study were also consistent with an increasingly hydrophobic microenvironment when Pluronic F127 was mixed with other surfactants. For example, the mixture of Pluronic F127 with D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) became more hydrophobic than Pluronic F127 or Vitamin E TPGS alone. Corresponding to this enhanced hydrophobicity, the mixture of Pluronic F127 and Vitamin E TPGS inhibited drug precipitation more than either individual component in a strongly synergistic effect (27).

If Pluronic F127 is combined with micelle-forming surfactants, it will interact with the surfactants, which increases the hydrophobicity of the mixed micelles, and thus strongly inhibits drug precipitation, as observed in the mixture of Pluronic F127 with Labrasol or Vitamin E TPGS (see Figure 4) (27). More studies are needed to further confirm this hypothesis using a large number of drugs and various surfactants. In addition to testing combinations of Pluronic F127 with various surfactants, it would be interesting to investigate how types and amounts of Pluronics affect the inhibition of drug precipitation. In the case of the Pluronic and Vitamin E TPGS mixture, Pluronic F127 and Pluronic F108, but not Pluronic F68, inhibited the compound precipitation in SIF. Pluronic F127 was the most potent drug-precipitation inhibitor (27). It would be interesting to analyze whether this finding proves true for other surfactants.


The addition of Pluronic F127 into the Labrasol formulations inhibited the precipitation of the tested compound upon dilution, and a synergistic effect on inhibiting drug precipitation was observed. The study results suggest that Pluronic F127 could be a potent inhibitor of drug precipitation for Labrasol formulations.

Wei-Guo Dai* is a fellow at Johnson & Johnson Pharmaceutical Research and Development, 145 King of Prussia Rd., Radnor, PA 19087. Liang C. Dong is chief scientific officer at ADDS Pharmaceuticals, and Abla A. Creasey is executive director of advanced technologies and regenerative medicine at Johnson & Johnson.

*To whom all correspondence should be addressed.

Submitted: Dec. 10, 2010. Accepted: Feb. 3, 2011.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here